Showing results (1241-1250 of 1,370) with videos related to

Sort By:
Pageof 137
Radiology|April 16, 2009
Imaging gene expression in human mesenchymal stem cells: from small to large animalsJürgen K Willmann, Ramasamy Paulmurugan, Martin Rodriguez-Porcel, et al.
Circulation Research|November 25, 2015
CDKN2B Regulates TGFβ Signaling and Smooth Muscle Cell Investment of Hypoxic NeovesselsVivek Nanda, Kelly P Downing, Jianqin Ye, et al.
Lancet (London, England)|February 27, 2015
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)Jeff S Healey, Stefan H Hohnloser, Michael Glikson, et al.
Stroke|June 8, 2013
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillationMasatsugu Hori, Stuart J Connolly, Jun Zhu, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 2, 2007
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failureAhmad Y Sheikh, Hyung J Chun, Alexander J Glassford, et al.
Circulation. Arrhythmia and Electrophysiology|October 4, 2022
Effects of Pulsed Electric Fields on the Coronary Arteries in SwineAdetola Ladejobi, Georgios Christopoulos, Nicholas Tan, et al.
Heart Rhythm O2|March 4, 2022
Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trialWilliam T Abraham, Jonathan P Piccini, Christopher Dufton, et al.
Circulation|January 24, 2024
Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial FibrillationSiddharth M Patel, Eugene Braunwald, Jan Steffel, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2018
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapyTianbao Lu, Carsten Schubert, Maxwell D Cummings, et al.
Journal of Medicinal Chemistry|November 7, 2000
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinaseA M Thompson, C J Connolly, J M Hamby, et al.
Pageof 137